close menu
X

Anfarm Hellas S.A. - Main Section

Anfarm Hellas S.A. - Main Component

Active Substance Strength Form
Bifonazole 0.005% Cr.Ext.Us
BrivaracetamUnder Development 10mg/ml Sol.Inf
BrivaracetamUnder Development 10mg/ml Oral Solution
Budesonide 0.025% (Tubx30g, x50g, x100g) Cr.Ext.Us
Budesonide 100mcg/Dose (FLx10ml (200 Doses)) Naspr.Sus
Butamirate Citrate 7.5mg/5ml (200ml Bottle) Syr

Alphabetically

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Active Substance Strength Form
Bifonazole 0.005% Cr.Ext.Us
BrivaracetamUnder Development 10mg/ml Sol.Inf
BrivaracetamUnder Development 10mg/ml Oral Solution
Budesonide 0.025% (Tubx30g, x50g, x100g) Cr.Ext.Us
Budesonide 100mcg/Dose (FLx10ml (200 Doses)) Naspr.Sus
Butamirate Citrate 7.5mg/5ml (200ml Bottle) Syr
Active Substance Strength Form Market Availability
Bifonazole 0.005% Cr.Ext.Us Selected Markets
BrivaracetamUnder Development 10mg/ml Sol.Inf Q4 2022
BrivaracetamUnder Development 10mg/ml Oral Solution Q1 2023
Budesonide 0.025% (Tubx30g, x50g, x100g) Cr.Ext.Us Selected Markets
Budesonide 100mcg/Dose (FLx10ml (200 Doses)) Naspr.Sus Selected Markets
Butamirate Citrate 7.5mg/5ml (200ml Bottle) Syr International